Rhythm Pharmaceuticals (RYTM) 2025 Conference May 14, 2025 12:20 PM ET Speaker0 Much for joining us. My name is Joanna Gajuk. I cover health care facilities managed care of America. Thanks so much for joining the conference and the session. So now a pleasure to to have Addus Home Care, so I'm pretty sure they would ask. They're one of the largest or maybe the largest provider of personal care services in The U. S, but they also do other things. We can talk about that. But today, we'd actually have an entire ...

-- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology (ESPE-ESE); 32nd annual European Congress on Obesity (ECO); and the 2025 annual meeting of the Pediatric Endocrine Society (PES 2025) -- BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharm ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-2159271 (State or o ...

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $2.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -17.39%. A quarter ago, it was expected that this company would post a loss of $0.69 per share when it actually produced a loss of $0.72, delivering a surprise of -4.35%.Over the last four quarters, the compan ...

Rhythm Pharmaceuticals (RYTM) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants David Connolly - Executive Director, Investor Relations and Corporate CommunicationsDavid Meeker - Chairman, President & CEOJennifer Lee - Executive Vice President, Head of North AmericaYann Mazabraud - Executive VP & Head of InternationalHunter Smith - Chief Financial OfficerJon Wolleben - Managing DirectorTazeen Ahmad - MD - US Equity ResearchSeamus Fernandez - Senior Managing DirectorWhitney Ijem - Managing ...

Rhythm Pharmaceuticals (RYTM) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Speaker0 Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Please be advised that today's conference is being recorded. After the speakers' presentation, there will be a question and answer session. I would now like to hand the conference over to your speaker today, David Connolly, Investo ...

Rhythm Pharmaceuticals First Quarter 2025 Financial Results and Business Update May 7, 2025 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. On Today's Call ® 2 • David Connolly, Executive Director of Investor Relations and Corporate Communications • David Meeker, MD, Chair, President and Chief Executive Officer • Jennifer Lee, Executive Vice President, Head of North America • Yann Mazabraud, Executive Vice President, Head of International • Hunter Smith, Chief Financial Officer Forward-looking Statem ...

EXHIBIT 99.1 Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update -- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quar ...

-- First quarter 2025 net product revenue from global sales of IMCIVREE (setmelanotide) of $37.7 million -- -- Cash on-hand expected to support planned operations into 2027 -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a ...

Rhythm Pharmaceuticals, Inc. (RYTM) shares ended the last trading session 5.2% higher at $62.97. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.2% gain over the past four weeks.The sudden rise in the stock price can be attributed to positive investor expectations regarding the continued strong sales growth of Rhythm Pharmaceuticals’ only marketed product, Imcivree (setmelanotide) injection, approved for treatin ...